Please login to the form below

Not currently logged in
Email:
Password:

RA

This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Most of the money raised will come from the SPAC itself, with approximately $75m to be raised through a private round with backers including Foresite, RA Capital Management, Frazier Life Sciences

Latest news

More from news
Approximately 9 fully matching, plus 155 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Similar retrospective positive findings were recently published for the anti-diabetic, glucagon-like peptide-1 receptor agonist (GLP1-RA), which was also found to reduce neuroinflammation.

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    and Rheumatoid Arthritis (RA). ... More than 400, 000 people in the UK live with RA (around 380, 000 in England), and it is recognised as a condition that can cause debilitating physical pain, affect mental

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).

  • European CTR implementation advances ethical assessment of clinical trials European CTR implementation advances ethical assessment of clinical trials

    Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 30 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...